NIP
IMVT icon

Nicholas Investment Partners’s Immunovant IMVT Stock Holding History

Nicholas Investment Partners’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33,103
Closed -$944K – 234
2024
Q3 		$944K Buy
+33,103
New +$976K 0.09% 186
2024
Q2 		– Sell
-137,682
Closed -$4.45M – 217
2024
Q1 		$4.45M Buy
137,682
+1,372
+1% +$50.1K 0.46% 84
2023
Q4 		$5.74M Sell
136,310
-241,845
-64% -$8.9M 0.67% 55
2023
Q3 		$14.5M Buy
+378,155
New +$8.55M 1.08% 32

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Nicholas Investment Partners's IMVT Position: Q4 2024 in Review

Nicholas Investment Partners sold out of Immunovant (IMVT) in Q4 2024, closing a stake of 33,103 shares — an estimated $944K sold.

Nicholas Investment Partners first reported a position in IMVT in Q3 2023 and held it in 4 quarters. The position peaked at $14.5M in Q3 2023. 186 funds tracked by Wall St. Rank hold IMVT as of Q4 2024.

  • Nicholas Investment Partners reported no remaining Immunovant position as of Q4 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 33,103 Immunovant shares in Q4 2024, an estimated $944K.
  • Nicholas Investment Partners first reported a position in Immunovant in Q3 2023 and held it in 4 quarters.
  • Nicholas Investment Partners's Immunovant position peaked at $14.5M in Q3 2023.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q4 2024.

Based on Nicholas Investment Partners's 13F filing for Q4 2024, filed 14 Feb 2025.